The Peripheral Nerve Injury drugs in development market research report provides comprehensive information on the therapeutics under development for Peripheral Nerve Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Peripheral Nerve Injury. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Peripheral Nerve Injury and features dormant and discontinued products.
GlobalData tracks 12 drugs in development for Peripheral Nerve Injury by 12 companies/universities/institutes. The top development phase for Peripheral Nerve Injury is preclinical with 11 drugs in that stage. The Peripheral Nerve Injury pipeline has nine drugs in development by companies and three by universities/ institutes. Some of the companies in the Peripheral Nerve Injury pipeline products market are: University of Calgary, Hokkaido University and BrainStorm Cell Therapeutics.
The key targets in the Peripheral Nerve Injury pipeline products market include Receptor Type Tyrosine Protein Phosphatase S, Vascular Endothelial Growth Factor, and GDNF Family Receptor Alpha 1.
The key mechanisms of action in the Peripheral Nerve Injury pipeline product include Insulin Like Growth Factor I Activator with one drug in Preclinical. The Peripheral Nerve Injury pipeline products include seven routes of administration with the top ROA being Oral and five key molecule types in the Peripheral Nerve Injury pipeline products market including Cell Therapy, and Small Molecule.
Peripheral Nerve Injury overview
Peripheral nerve injuries pose various challenges to patients, ranging from mild discomfort to life-long impairment. Peripheral nerve injuries include brachial plexus injury, peroneal nerve injury (foot drop), and spinal accessory nerve injury.
For a complete picture of Peripheral Nerve Injury’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
